Ascletis Pharma Stock Last Dividend Paid
| ASCLF Stock | USD 0.24 0.06 33.33% |
Ascletis Pharma fundamentals help investors to digest information that contributes to Ascletis Pharma's financial success or failures. It also enables traders to predict the movement of Ascletis Pink Sheet. The fundamental analysis module provides a way to measure Ascletis Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ascletis Pharma pink sheet.
Ascletis |
Ascletis Pharma Company Last Dividend Paid Analysis
Ascletis Pharma's Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Ascletis Pharma has a Last Dividend Paid of 0.0. This indicator is about the same for the Healthcare average (which is currently at 0.0) sector and about the same as Biotechnology (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Instant Ratings Now
Instant RatingsDetermine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Ascletis Fundamentals
| Return On Equity | -0.0632 | |||
| Return On Asset | -0.053 | |||
| Profit Margin | (2.24) % | |||
| Operating Margin | (3.11) % | |||
| Current Valuation | 116.15 M | |||
| Shares Outstanding | 1.09 B | |||
| Shares Owned By Insiders | 67.02 % | |||
| Shares Owned By Institutions | 1.94 % | |||
| Price To Book | 1.58 X | |||
| Price To Sales | 7.61 X | |||
| Revenue | 76.88 M | |||
| Gross Profit | 39.17 M | |||
| EBITDA | (169.35 M) | |||
| Net Income | (199.02 M) | |||
| Cash And Equivalents | 2.5 B | |||
| Cash Per Share | 2.28 X | |||
| Total Debt | 2.75 M | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 28.93 X | |||
| Book Value Per Share | 2.50 X | |||
| Cash Flow From Operations | (146.93 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 315 | |||
| Beta | 0.81 | |||
| Market Capitalization | 672.93 M | |||
| Total Asset | 2.83 B | |||
| Net Asset | 2.83 B |
About Ascletis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascletis Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascletis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascletis Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Ascletis Pink Sheet
Ascletis Pharma financial ratios help investors to determine whether Ascletis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ascletis with respect to the benefits of owning Ascletis Pharma security.